BACKGROUND: The objective of this systematic review is to determine whether @entity28 @entity1 who use progestogen-only contraceptives are more likely to experience @entity1017 or serious adverse events as compared to nonobese users. STUDY DESIGN: We searched PubMed for all articles (in all languages) published in peer-reviewed journals from database inception through October 2008, for evidence relevant to @entity28 and progestogen-only contraceptives. We used standard abstract forms and grading systems to summarize and assess the quality of the evidence. RESULTS: From 579 articles, we identified nine studies fitting our selection criteria. Evidence from five studies suggests that among adult @entity1 , baseline weight or body mass index is not associated with @entity1017 among depot @entity11796 ( @entity12135 ) users (Level II-2, Fair). Evidence from three studies suggests that among adolescent @entity1 , overweight or @entity28 @entity12135 users may gain more weight than normal weight @entity12135 users or overweight/ @entity28 nonusers (Level II-2, Fair). Evidence from one small study of Norplant users showed no differences in @entity1017 by baseline weight (Level II-3, Poor). We did not identify studies of other progestogen-only contraceptive methods that examined weight change by baseline weight, nor did we identify studies that reported on any serious adverse events by baseline weight. CONCLUSIONS: Adolescent @entity12135 users who are @entity28 may gain more weight than normal weight users. This observation was not seen in adult @entity12135 users or adolescent Norplant users.

Progestogen-only contraceptive use in XXXX @entity1 .

@entity1 :: ('9606', 'Species') :: ['women'] @entity11796 :: ('MESH:D017258', 'Chemical') :: ['medroxyprogesterone acetate'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obese', 'obesity'] @entity1017 :: ('MESH:D015430', 'Disease') :: ['weight gain'] @entity12135 :: ('MESH:C050795', 'Chemical') :: ['DMPA']
@entity28 :: (MESH:D009765,Disease) :: ['obese']
